Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2025-09-09 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
内部审计制度
Audit Report / Information Classification · 95% confidence The document is titled '内部审计制度' (Internal Audit System) and details the internal audit policies, procedures, responsibilities, and organizational structure of the company. It includes sections on audit scope, audit committee roles, audit procedures, reporting, and penalties for violations. The document is a formal internal control and audit policy document approved by the board, not a financial report or announcement of financial results. It does not contain financial statements or results, nor is it a brief announcement or certification. It is a detailed internal audit system document, which fits the category of Audit Report / Information (AR) as it relates to internal audit policies and procedures rather than a full annual report or other categories. Q3 2025
2025-09-09 Chinese
董事、高级管理人员离职管理制度
Governance Information Classification · 95% confidence The document is titled '董事、高级管理人员离职管理制度' which translates to 'Board and Senior Management Departure Management System'. It details the internal management system regarding the resignation, dismissal, and departure procedures of directors and senior management personnel. The content includes rules, responsibilities, and procedures related to board and senior management changes, but it is not an announcement of a specific personnel change, nor is it a financial report or regulatory filing about a specific event. It is a governance-related document outlining internal rules and policies for board and management departures. Therefore, it fits best under the category of Governance Information (CGR). The document length is 3053 characters, which is sufficient for a detailed policy document rather than a brief announcement or certification. There is no indication that this is a report publication announcement or a regulatory filing. Hence, the classification is CGR with high confidence.
2025-09-09 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' (Public Opinion Management System) and details internal management policies related to handling public opinion and media crises. It includes sections on organizational structure, responsibilities, principles, and procedures for managing public opinion and related risks. The document is a formal announcement of an internal management system approved by the company's board of directors on September 8, 2025. It does not contain financial data, audit information, voting results, or any report publication notice. It is not a financial report, regulatory filing, or announcement of voting results. The content is about internal governance and management policies, specifically related to public opinion management. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3509 characters, which is relatively short but contains substantive policy content, not just an announcement or certification.
2025-09-09 Chinese
信息披露暂缓、豁免管理制度
Governance Information Classification · 95% confidence The document is a formal announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the adoption of an internal management system titled 'Information Disclosure Delay and Exemption Management System.' It details the board meeting resolution, the content of the new internal policy, and procedural rules for delaying or exempting information disclosure. The document does not contain financial statements, earnings data, or regulatory filings of financial results. It is a governance-related announcement about internal rules and procedures for information disclosure management. Therefore, it fits best under Governance Information (CGR). The document length is 2689 characters, which is relatively short and consistent with a policy announcement rather than a full report.
2025-09-09 Chinese
关于取消监事会、调整董事会成员人数暨修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding changes to the company's articles of association (company bylaws), including adjustments to the board of directors and the cancellation of the supervisory board. It contains extensive legal and governance-related content, referencing company law, securities law, and listing rules. The document does not present financial statements, audit results, earnings data, or investor presentations. Instead, it focuses on corporate governance structure, shareholder rights, board composition, and related regulatory compliance. Therefore, it fits best into the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-09-09 Chinese
第四届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the 4th Board of Directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to amendments to company bylaws and internal management systems. The content focuses on board decisions, governance structure changes, and appointments, without presenting financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or audit report. The document is a formal disclosure of board meeting resolutions, which fits the category of Board/Management Information (MANG).
2025-09-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.